photodynamic

Methyl Aminolevulinate Hydrochloride (5-Aminolevulinic acid methyl ester) is commonly used in photosentizer reagents for photodynamic therapy to treat conditions such as Acne vulgaris and hypertrophic scarring.

Verteporfin (BPD-MA) is a YAP inhibitor that inhibits YAP-TEAD interactions. Verteporfin is also a photosensitizer used in photodynamic therapy. Verteporfin also induces apoptosis and inhibits autophagy.

PPA-904, a specific phenothiazine photosensitizer, is used in photodynamic therapy (PDT).

PPA-904 FA is a cationic photosensitizer with broad-spectrum antimicrobial activity for use in photodynamic studies (PDT) studies, which can be used to study chronic leg ulcers and diabetic foot ulcers.

Methylene Violet 3RAX is a cationic dye, a potential photosensitizer in photodynamic therapy, with antitumor activity that alters the molecular structure of DNA, disrupts the modules of DNA, and induces the production of reactive monoclinic oxygen species, which are used to stain the mitochondria of cells.Methylene Violet 3RAX inhibits the subcellular localization of cancer cells by severing the Methylene Violet 3RAX inhibits subcellular localization of cancer cells, leading to cell death by cutting DNA strands in tumor cells.

GPLGIAGQ acetate is a MMP2-cleavable polypeptide. GPLGIAGQ acetate can be used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy.

HPPH (Photochlor) (Photochlor) is a second-generation photosensitizer. It is used as photodynamic therapy (PDT) agent.

Talaporfin is a photosensitizer used in photodynamic therapy.

Temoporfin used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck.

Methyl aminolevulinate is a prodrug that can be metabolized to Protoporphyrin IX. Methyl aminolevulinate is an agent used as a sensitizer in photodynamic therapy (PDT).

Pyropheophorbide-a (Ppa) shows promise as a photosensitizer in tumor photodynamic therapy (PDT).

Antitumor agent-187 (compound I3), a photosensitizer derived from 5,15-diarylporphyrin, exhibits anticancer activity with a peak absorption wavelength of ~668 nm. This compound induces apoptosis and is applicable in photodynamic therapy (PDP). It selectively accumulates in tumor sites and possesses real-time fluorescence imaging capabilities.

Photosensitizer-5, a photodynamic agent, exhibits cytotoxicity towards HeLa and HepG2 cells, with IC50 values of 10.4 nM and 6.9 nM, respectively. It induces cell death through lipid peroxidation via an iron-independent ferroptosis pathway. Additionally, Photosensitizer-5 displays antitumor activity in HeLa-tumor-bearing mice.

Ferroptosisinducer 6 (6d) is an inducer of ferroptosis (ferroptosis) that exhibits potent potential for Type I/II photodynamic therapy by inducing ROS production, oxidative stress, and mitochondrial damage. Additionally, it demonstrates antitumor activity.

NA-Ir is a ferroptosis (Ferroptosis) inducer that targets mitochondrial DNA (mtDNA) and activates the cGAS-STING pathway to stimulate ferritin autophagy (). It also induces the production of reactive oxygen species (ROS) through photodynamic therapy (PDT), depletes glutathione (GSH), and downregulates glutathione peroxidase 4 (GPX4), thereby triggering lipid peroxidation and ferroptosis. NA-Ir exhibits enhanced anticancer activity under light exposure and selectively inhibits cancer cells with high H2S content.

Protoporphyrin IX disodium, as a radiation sensitizer, enhances the production of ROS and induces DNA damage even under hypoxic conditions. It also acts as a photosensitizer, undergoing direct degradation through photobleaching upon light exposure. This compound accumulates in rat tumor cells following administration of 5-aminolevulinic acid (5-ALA). When activated with a peak wavelength of 405 nm, Protoporphyrin IX disodium selectively improves basal cell carcinoma. It shows promise in pharmacological research of sonodynamic and photodynamic therapy for cancers such as bladder cancer and nodular basal cell carcinoma.

Silicon naphthalocyanine dichloride is a photosensitizer with potential anti-tumor activity. This compound is employed in photodynamic therapy to inhibit cancer by effectively absorbing specific wavelengths of light, thereby generating oxygen radicals that aid in the destruction of cancer cells. The biocompatibility of Silicon naphthalocyanine dichloride demonstrates promising prospects for medical applications.

CQ-ER is a Coumarin-quinazolinone-based photosensitizer targeting the endoplasmic reticulum (ER). It induces ferroptosis, thereby enhancing photodynamic therapy (PDT).

YRN84347, also known as meso-Tetra (3,5-dimethoxyphenyl) porphine, is a synthetic porphyrin compound and photosensitizer. With a high yield of singlet oxygen, this compound shows potential applications in photodynamic therapy for cancer and other related human diseases.

5,10,15,20-Tetrakis(4-methoxyphenyl)porphyrin is a porphyrin derivative capable of forming complexes with metal ions such as zinc (Zn), copper (Cu), and cadmium (Cd). These metal complexes exhibit phototoxicity towards Hep-2 cells, causing cell inactivation through the generation of singlet oxygen.

Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.

LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).

TBC-1 is a chlorophyll-a derivative that acts as a photosensitizer for photodynamic therapy (PDT). It efficiently generates type I ROS and targets the endoplasmic reticulum. TBC-1 demonstrates in vitro biocompatibility and PDT effectiveness under both normoxic and hypoxic conditions.

CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LD). It exhibits phototoxicity against breast cancer cells with an IC50 of 0.01-0.02 μM and demonstrates antitumor efficacy in a 4T1 xenograft mouse model.